Stoke Therapeutics, Inc. (STOK) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

CorMedix, Inc.

Carisma Therapeutics, Inc.

Invivyd, Inc.

Fate Therapeutics, Inc.

Foghorn Therapeutics, Inc.

Stoke Therapeutics, Inc.

Taysha Gene Therapies, Inc.

Vigil Neuroscience, Inc.

Larimar Therapeutics, Inc.

Neoleukin Therapeutics, Inc.

Ikena Oncology, Inc.

Why is Stoke Therapeutics, Inc. ?

Poor Management Efficiency with a low ROE of 2.87%

The company has been able to generate a Return on Equity (avg) of 2.87% signifying low profitability per unit of shareholders funds

With a fall in Net Sales of -86.49%, the company declared Very Negative results in Mar 26

The company has declared negative results for the last 2 consecutive quarters
INTEREST(HY) At USD 0.03 MM has Grown at 2,500%
NET SALES(Q) At USD 6.23 MM has Fallen at -86.49%
PRE-TAX PROFIT(Q) At USD -50 MM has Fallen at -2,805.04%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 167.93%, its profits have risen by 92.3%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Stoke Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Stoke Therapeutics, Inc.

167.93%

1.59

67.93%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

184.20%

EBIT Growth (5y)

10.02%

EBIT to Interest (avg)

-67.33

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

0.28

Tax Ratio

2.48%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

2.87%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.51

EV to EBIT

-80.67

EV to EBITDA

-101.20

EV to Capital Employed

23.63

EV to Sales

9.01

PEG Ratio

Dividend Yield

ROCE (Latest)

-29.29%

ROE (Latest)

-1.95%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

CASH AND EQV(HY)

Highest at USD 628.71 MM

-37What is not working for the Company

INTEREST(HY)

At USD 0.03 MM has Grown at 2,500%

NET SALES(Q)

At USD 6.23 MM has Fallen at -86.49%

PRE-TAX PROFIT(Q)

At USD -50 MM has Fallen at -2,805.04%

NET PROFIT(Q)

At USD -50 MM has Fallen at -2,805.04%

OPERATING CASH FLOW(Y)

Lowest at USD -146.82 MM

RAW MATERIAL COST(Y)

Grown by 16.41% (YoY

DEBTORS TURNOVER RATIO(HY)

Lowest at 9.51 times

Here's what is working for Stoke Therapeutics, Inc.

Cash and Eqv

Highest at USD 628.71 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Here's what is not working for Stoke Therapeutics, Inc.

Interest

At USD 0.03 MM has Grown at 2,500%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Sales

At USD 6.23 MM has Fallen at -86.49%

over average net sales of the previous four periods of USD 46.1 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -50 MM has Fallen at -2,805.04%

over average net sales of the previous four periods of USD -1.72 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -50 MM has Fallen at -2,805.04%

over average net sales of the previous four periods of USD -1.72 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow

Lowest at USD -146.82 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Debtors Turnover Ratio

Lowest at 9.51 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 16.41% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales